

Table S1 Laboratory findings

Parameters	Hemoptysis	n [†]	Infective exacerbation	n [†]	P value
WBC count, / μ L	7,360 [5,890–9,460]	267	10,550 [7,790–14,650]	223	<0.001
ESR, mm/h	22 [11–43]	266	65 [43–97]	220	<0.001
C-reactive protein, mg/dL	0.27 [0.10–1.50]	267	8.91 [3.89–17.86]	222	<0.001
Procalcitonin, ng/mL	0.039 [0.025–0.060]	127	0.174 [0.072–0.571]	197	<0.001
NT-proBNP, pg/mL	108 [55–254]	142	565 [192–1455]	200	<0.001
Hemoglobin, g/dL	12.7 [11.6–13.7]	267	11.9 [10.8–13.1]	223	<0.001
Platelet, $10^3/\mu$ L	235 [193–273]	267	261 [188–354]	223	<0.001
Albumin, g/dL	4.2 [3.9–4.4]	267	3.6 [3.2–3.9]	223	<0.001
Total protein, g/dL	7.4 [7.0–7.8]	267	7.4 [6.8–7.9]	223	0.501
AST, U/L	22 [18–27]	267	23 [17–32]	223	0.365
ALT, U/L	15 [11–21]	267	16 [10–24]	223	0.679
BUN, mg/dL	14.0 [11.4–17.6]	267	16.9 [12.0–22.3]	223	<0.001
Creatinine, mg/dL	0.69 [0.59–0.85]	267	0.83 [0.64–1.08]	223	<0.001
Sodium, mmol/L	139 [136–140]	267	135 [132–137]	223	<0.001

Data are presented as median [interquartile range]. [†], the numbers of patients who performed each laboratory test were indicated. WBC, white blood cell; ESR, erythrocyte sedimentation rate; NT-proBNP, N-terminal prohormone of brain natriuretic peptide; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; BUN, blood urea nitrogen.

Table S2 Baseline and radiological characteristics between survivors and non-survivors at 30 days (n=490)

Characteristics	Survivors (n=466)	Non-survivors (n=24)	P value
Age, years	69 [61–76]	75 [70–81]	0.001
Male sex	247 (53.0)	19 (79.2)	0.012
Smoking			
Ever-smoker	190 (41.0)	13 (56.5)	0.142
Pack-years	0 [0–25]	10 [0–45]	0.065
BMI (kg/m ²)	21.3 [19.1–23.9]	17.8 [15.1–21.4]	0.001
Excessive alcohol use	34 (7.5)	3 (13.6)	0.240
ECOG	1 [1–2]	3 [2–4]	<0.001
Colonization			
<i>Pseudomonas aeruginosa</i>	33 (7.1)	0 (0.0)	0.394
Other pathogens	13 (2.8)	0 (0.0)	>0.999
Symptoms at presentation			
Duration of symptom, days	3 [1–5]	3 [1–7]	0.434
Cough	373 (80.0)	22 (91.7)	0.194
Sputum production	315 (67.6)	23 (95.8)	0.004
Dyspnea	250 (53.6)	22 (91.7)	<0.001
Fever	132 (28.3)	10 (41.7)	0.160
Altered mental status	10 (2.1)	5 (20.8)	<0.001
Chest pain	43 (9.2)	2 (8.3)	>0.999
Hemoptysis	263 (56.4)	4 (16.7)	<0.001
CT findings			
Modified Reiff score	4 [2–7]	7 [4–10]	0.018
Number of involved lobes	3 [2–4]	4 [2–4]	0.116
≥3 involved lobes	285 (61.2)	18 (75.0)	0.173
Cystic bronchiectasis	201 (43.1)	17 (70.8)	0.008
Mycetoma	46 (9.9)	3 (12.5)	0.723
TB destroyed lung	32 (6.9)	8 (33.3)	<0.001
Emphysema	119 (25.5)	13 (54.2)	0.002
Bronchial anthracofibrosis	68 (14.6)	1 (4.2)	0.228
Bronchial artery hypertrophy on enhanced CT	176/424 (41.5)	6/17 (35.3)	0.610
Etiology			
Idiopathic	165 (35.4)	9 (37.5)	0.835
Previous pulmonary TB	189 (40.6)	13 (54.2)	0.187
Previous NTM pulmonary disease	19 (4.1)	0 (0.0)	0.615
Post-infectious	68 (14.6)	0 (0.0)	0.061
COPD	14 (3.0)	2 (8.3)	0.182
Others [†]	11 (2.4)	0 (0.0)	>0.999

Data are presented as median [interquartile range] or n (%). [†], others include rheumatoid arthritis [6 (1.3%) vs. 0 (0.0%)], Mounier-Kuhn syndrome [1 (0.2%) vs. 0 (0.0%)], diffuse panbronchiolitis [3 (0.6%) vs. 0 (0.0%)], and Kartagener's syndrome [1 (0.2%) vs. 0 (0.0%)]. BMI, body mass index; ECOG, Eastern Cooperative Oncology Group performance status; CT, computed tomography; TB, tuberculosis; NTM, nontuberculous mycobacterial; COPD, chronic obstructive pulmonary disease.